Treatment of canine cutaneous leishmaniasis by Leishmania (Viannia) braziliensis in dogs with furazolidone and β-cyclodextrin: case report.
DOI:
https://doi.org/10.12834/VetIt.2239.15416.2Keywords:
American cutaneous leishmaniasis, Dogs, Nitrofurans, TherapyAbstract
Euthanasia of animals is not accepted as a control for cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis and drugs used in humans for the treatment of leishmaniasis are not allowed for animals in Brazil. Miltefosine was authorized for dogs infected by Leishmania infantum with variable results for L. braziliensis. Thus, nine dogs infected with Leishmania (V.) braziliensis were treated by a combination of furazolidone and β-cyclodextrin. The nine dogs were mongrels, weighing between 4-17 kg and 3-10 years old. These dogs had ulcerous lesions in different regions such as scrotal tissue, auricular pavilion and nostrils. Serological, molecular and protozoal culture techniques were used for laboratory diagnosis. The treatment used furazolidone + β-cyclodextrin complex (1: 2) at a concentration of 60 mg/mL given orally at a dose of 15 mg/kg every 12 hours. The re-epithelialization of lesions occurred between 35 and 41 days of treatment. During fourteen months the animals were monitored and there was no reactivation of lesions or growth of the protozoan in a culture medium of the biopsies. This study demonstrated that treatment with FZD and CD is effective in reducing the cutaneous lesions caused by L. braziliensis in dogs.
References
References
Brasil. Ministério da Agricultura Pecuária e Abastecimento (MAPA).2016. http://portalarquivos.saude.gov.br/images/pdf/2016/setembro/23/NT-informativa-Milteforan--002-...pdf
Brasil. Ministério da Saúde. 2017. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de vigilância da leishmaniose tegumentar(http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_tegumentar.pdf)
Carvalho S.G., Siqueira L.A., Zanini M.S., Dos Santos Matos A.P., Quaresma C.H., da Silva L.M., de Andrade S.F., Severi J.A. & Villanova J.C.O. 2018. Physicochemical and in vitro biological evaluations of furazolidone-based β-cyclodextrin complexes in Leishmania amazonensis. Res Vet Sci, 119, 143-153.
Coelho L.G., Maguinilk I., Zaterka S., Parente J.M., do Carmo Friche, Passos M. & Moraes-Filho J.P. 2013. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol, 50, 2.
Daza González M.A., Fragío Arnold C., Fermín Rodríguez M., Checa R., Montoya A., Portero Fuentes M., Rupérez Noguer C., Martínez Subiela S., Cerón J.J. & Miró G. 2019. Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis. Vet J, 245, 22-28.
de Bruijn M.H. & Barker D.C. 1992. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Trop, 52 (1), 45–58.
Espada C.R., Ribeiro-Dias F., Dorta M.L., Pereira L.I.A., Carvalho E.M., Machado P.R., Schriefer A., Yokoyama-Yasunaka J.K.U., Coelho A.C. & Uliana S.R.B. 2017. Susceptibility to miltefosine in brazilian clinical isolates of Leishmania (Viannia) braziliensis. Am J Trop Med Hyg, 96 (3), 656-659.
Espada C.R., Magalhães R.M., Cruz M.C., Machado P.R., Schriefer A., Carvalho E.M., Hornillos V., Alves J.M., Cruz A.K., Coelho A.C. & Uliana S.R.B. 2019. Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake. Int J Parasitol Drugs Drug Resist, 11, 139–147.
Hunder G., Schmid A. & Mayring L. 1987. Investigation on the metabolic degradation of the side chain of furazolidone. Archives Toxicology, 61 (2), 161-163.
Minodier P & Parola P. 2007. Cutaneous leishmaniasis treatment. Travel Med Infect Dis, 5 (3), 150-158.
Pan American Health Organization (PAHO). 2020. Cutaneous and Mucosal Leishmaniasis.(https://www.paho.org/hq/index.php?option=com_content&view=article&id=6417&Itemid=39345&lang=en (acessed on 15 April 2020)
Passos S.R., Rodrigues T.A., Madureira A.P., Giunchetti R.C. & Zanini M.S. 2014. Clinical treatment of cutaneous leishmaniasis in dogs with furazolidone and domperidone. Int J Antimicrob Agents, 44 (5),463-465.
Ribeiro F.C., de O. Schubach A., Mouta-Confort E., Schubach T.M., de Fátima Madeira M. & Marzochi M.C. 2007. Use of ELISA employing Leishmania (Viannia) braziliensis and Leishmania (Leishmania) chagasi antigens for the detection of IgG and IgG1 and IgG2 subclasses in the diagnosis of American tegumentary leishmaniasis in dogs. Vet Parasitol, 148, 200-206.
Tempone A.G., Mortara Andrade Jr H.H. & Reimão J.Q. 2010. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. Int J Antimicrob Agents, 36 (2), 159-163.
Zanini M.S., Viana K.F., Reis A.B., Campos D.R., Mussi J.M., Zanini S. & Lemos E.M. 2010. Leishmania (Viannia) braziliensis: immunoblotting analysis for the detection of IgG subclasses in the diagnosis of symptomatic and asymptomatic dogs. Vet Parasitol, 173, 143-146.
Vidal I.F., Martins I.V., Lira R.A., Teixeira M.N., Faustino M.A.G. & L.C. Alves. 2009. Serum levels of gamma-glutamyl transferase in dogs naturally infected or not by Leishmania (Leishmania) chagasi. Arq Bras Med Vet Zootec, 61, 749-751.
